PT-141 vs Melanotan II
PT-141 (bremelanotide) and Melanotan II are both melanocortin receptor agonists studied for sexual health applications, but they have very different profiles. PT-141 is a targeted derivative of Melanotan II that was specifically developed for sexual function research — it's now FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Melanotan II is the broader parent compound that activates multiple melanocortin receptors, producing tanning, appetite suppression, and sexual arousal effects simultaneously. PT-141 was derived from Melanotan II to isolate the sexual function effects with fewer off-target activities.
Similarities
- =Both are synthetic melanocortin receptor agonists
- =Both activate MC3R and MC4R receptors involved in sexual arousal
- =Both are derived from alpha-MSH (alpha-melanocyte-stimulating hormone)
- =PT-141 was directly derived from Melanotan II research
- =Both are administered via subcutaneous injection in research protocols
- =Both show effects on sexual arousal through central nervous system mechanisms
Key Differences
| Aspect | PT-141 | Melanotan II |
|---|---|---|
| Receptor Selectivity | More selective for MC3R/MC4R (sexual function receptors) | Non-selective — activates MC1R (tanning), MC3R, MC4R, MC5R |
| FDA Status | FDA-approved (Vyleesi) for HSDD in premenopausal women | Not FDA-approved for any indication |
| Tanning Effect | Minimal to none | Significant skin darkening via MC1R activation |
| Appetite Effects | Minimal | Appetite suppression reported in studies |
| Nausea | Common side effect (~40% in clinical trials) | Also reported, especially at higher doses |
| Duration of Effect | Onset ~45 min, duration several hours | Longer-acting due to broader receptor activation |
| Research Maturity | Full FDA clinical trial program completed | Studied but never advanced through FDA approval |
Which to Choose for Your Research
Sexual function research (controlled)
PT-141PT-141 has completed Phase III clinical trials and FDA approval, providing the most rigorous efficacy and safety data for sexual function research.
Melanocortin system research (broad)
Melanotan IIMelanotan II activates a wider range of melanocortin receptors, making it useful for studying the melanocortin system broadly rather than targeting one specific endpoint.
Skin pigmentation research
Melanotan IIOnly Melanotan II significantly activates MC1R, the receptor responsible for melanogenesis and tanning. PT-141 has minimal tanning effects.
Female sexual health research
PT-141PT-141 (Vyleesi) is the only FDA-approved peptide for HSDD in women, with RECONNECT trial data specifically in premenopausal female subjects.
Appetite/metabolic research
Melanotan IIMelanotan II's broader receptor profile includes appetite-suppressing effects via MC4R and MC3R activation that are more pronounced than PT-141's.
The Verdict
PT-141 is the more refined, clinically validated compound for sexual health research. With FDA approval and completed Phase III trials, it offers the strongest evidence base and most predictable safety profile. Melanotan II is a broader melanocortin agonist useful for researching the full melanocortin system — including tanning, appetite, and sexual function together — but lacks the controlled clinical data of PT-141.
For focused sexual function research, PT-141 is the clear choice. For broader melanocortin receptor research, Melanotan II offers a wider pharmacological profile.
Frequently Asked Questions
Is PT-141 derived from Melanotan II?
Yes. PT-141 (bremelanotide) was developed from Melanotan II by Palatin Technologies. Researchers identified that Melanotan II's sexual arousal effects were mediated by MC3R/MC4R activation, and modified the molecule to be more selective for those receptors while reducing tanning and other off-target effects.
Does Melanotan II require UV exposure for tanning?
Melanotan II stimulates melanogenesis (melanin production) via MC1R activation. Some UV exposure enhances the tanning effect, but melanin production can occur without it. Research protocols vary on UV co-exposure.
Why does PT-141 cause nausea?
Nausea is the most common side effect of PT-141, reported in ~40% of subjects in clinical trials. It's thought to be related to melanocortin receptor activation in the brainstem area postrema. The effect is typically transient and dose-dependent.
Which is cheaper from research vendors?
Melanotan II is generally cheaper per vial since it's an older, non-patented compound. PT-141 tends to be priced higher. Check our vendor price comparison pages for current pricing across verified suppliers.
PT-141
View full compound page with vendor pricing.
Compare 18 products →Melanotan II
View full compound page with vendor pricing.
Compare 14 products →For research reference only. Not medical advice. Not for human consumption. All compounds discussed are research chemicals.